Mycrodose Therapeutics - Advanced Delivery Systems for Ketamine, Psilocybin and other Psychedelics

Mycrodose Therapeutics is a US-Based pharmaceutical company specializing in the development of Advanced Drug Delivery (ADD) systems for psychedelic compounds.  

On this episode of The Integration Conversation, Mycrodose's Chad Conner and Patrick Eckstrom join Brom to discuss how ADD systems can potentially improve the patient experience, increase the safety profile and lower the cost of psychedelic drugs.  

💰 Invest in Brom's Psychedelic VC Fund:
https://www.empath.vc

🎧 Listen on Spotify and other podcast platforms:
https://anchor.fm/theintegrationco

🐦 brom on twitter:
https://twitter.com/therealbrom

🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco

💌 Email:  
hello@empath.vc

⏰ Timestamps:
2:15 - Chad and Patrick's backgrounds
10:00 - What is Advanced Drug Delivery?
14:00 - Mycrodose's Pipeline
17:00 - Transdermal Psilocybin & LSD
26:30 - Competition in ADD space
30:00 - IP around transdermal delivery
31:00 - Cannabis vs Psychedelics
35:00 - Mycrodose's Business Strategy
38:00 - Where is Mycrodose now, and what should we look forward to?

‍